NYSE Arca · USNZ

Xtrackers Net Zero Pathway Paris Aligned US Equity ETF (USNZ)

$48.84−0.88%
Close Sep 28, 2026 · split-adjusted
Sep 28, 2026$48.84▲ 16.05% in range
Sep 29, 2025Low $38.98 · High $49.48Sep 28, 2026
What changed · written from our data
As of Sep 28, 2026

Xtrackers Net Zero Pathway Paris Aligned US Equity ETF closed at $48.84 on Sep 28, down 0.88%, 1.3% below its 52-week closing high. Volume of 45 shares was 0.25× its 20-day average (below normal).

Split-adjusted performance: -0.3% over one month, +24.9% over six months, +17.2% over one year.

Short interest was 174 shares at the Sep 15 settlement, down 64.3% from the prior report (1.0 days to cover).

Market cap$300.4M6.2M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yield0.84%$0.1027 last paid
52-week range38.98 – 49.48−1.3% from high
Volume450.25× 20-day avg
Volatility · 60d12.6%Annualised
Short % of float—1.0 days to cover
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W −1.2%1M −0.3%3M +4.3%6M +24.9%YTD +12.8%1Y +17.2%3Y +76.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within industry

Not enough peers to rank

6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—

Short interest

Details →
Shares short174−64.3% vs prior
Days to cover1.0Settled Sep 15
% of float—
Short vol. 10d51.5%of daily volume

News about Xtrackers Net Zero Pathway Paris Aligned US Equity ETF

All news →

No recent articles focused on Xtrackers Net Zero Pathway Paris Aligned US Equity ETF.

Quick answers

What is USNZ's market cap?
$300.37M, based on the Sep 28 close of $48.84.
Does Xtrackers Net Zero Pathway Paris Aligned US Equity ETF pay a dividend?
Yes. The latest regular dividend was $0.1027 per share (ex-date Sep 18), an annualised yield of 0.84%.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology